Literature DB >> 33823069

Activity of venetoclax against relapsed acute undifferentiated leukemia.

Kenneth J Caldwell1, Amit Budhraja2, Joseph T Opferman2, Ching-Hon Pui1, Jeffery M Klco3, Jeffrey E Rubnitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33823069      PMCID： PMC9158737          DOI： 10.1002/cncr.33531

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.921


× No keyword cloud information.
  10 in total

1.  Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.

Authors:  Ayman Qasrawi; Victor Gomes; Charles Andrew Chacko; Akila Mansour; Melissa Kesler; Ranjana Arora; Sainan Wei; Reshma Ramlal; Reinhold Munker
Journal:  Leuk Res       Date:  2020-01-17       Impact factor: 3.156

2.  Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Shuhei Kurosawa; Takashi Toya; Yuya Kishida; Akihito Nagata; Yuta Yamada; Tatsuya Konishi; Satoshi Kaito; Kota Yoshifuji; Naoki Matsuyama; Shuichi Shirane; Tomoyuki Uchida; Kyoko Inamoto; Aiko Igarashi; Yuho Najima; Hideharu Muto; Takeshi Kobayashi; Noriko Doki; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Leuk Lymphoma       Date:  2018-04-04

3.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

Review 4.  BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.

Authors:  Victoria Del Gaizo Moore; Anthony Letai
Journal:  Cancer Lett       Date:  2012-01-08       Impact factor: 8.679

5.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.

Authors:  Seth E Karol; Thomas B Alexander; Amit Budhraja; Stanley B Pounds; Kristin Canavera; Lei Wang; Joshua Wolf; Jeffery M Klco; Paul E Mead; Soumyasri Das Gupta; Su Y Kim; Ahmed Hamed Salem; Tammy Palenski; Norman J Lacayo; Ching-Hon Pui; Joseph T Opferman; Jeffrey E Rubnitz
Journal:  Lancet Oncol       Date:  2020-03-11       Impact factor: 41.316

8.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Authors:  Rongqing Pan; Leah J Hogdal; Juliana M Benito; Donna Bucci; Lina Han; Gautam Borthakur; Jorge Cortes; Daniel J DeAngelo; Lakeisha Debose; Hong Mu; Hartmut Döhner; Verena I Gaidzik; Ilene Galinsky; Leonard S Golfman; Torsten Haferlach; Karine G Harutyunyan; Jianhua Hu; Joel D Leverson; Guido Marcucci; Markus Müschen; Rachel Newman; Eugene Park; Peter P Ruvolo; Vivian Ruvolo; Jeremy Ryan; Sonja Schindela; Patrick Zweidler-McKay; Richard M Stone; Hagop Kantarjian; Michael Andreeff; Marina Konopleva; Anthony G Letai
Journal:  Cancer Discov       Date:  2013-12-17       Impact factor: 39.397

9.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Brian A Jonas; Vinod Pullarkat; Michael J Thirman; Jacqueline S Garcia; Andrew H Wei; Marina Konopleva; Hartmut Döhner; Anthony Letai; Pierre Fenaux; Elizabeth Koller; Violaine Havelange; Brian Leber; Jordi Esteve; Jianxiang Wang; Vlatko Pejsa; Roman Hájek; Kimmo Porkka; Árpád Illés; David Lavie; Roberto M Lemoli; Kazuhito Yamamoto; Sung-Soo Yoon; Jun-Ho Jang; Su-Peng Yeh; Mehmet Turgut; Wan-Jen Hong; Ying Zhou; Jalaja Potluri; Keith W Pratz
Journal:  N Engl J Med       Date:  2020-08-13       Impact factor: 91.245

10.  Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Authors:  Heikki Kuusanmäki; Aino-Maija Leppä; Petri Pölönen; Mika Kontro; Olli Dufva; Debashish Deb; Bhagwan Yadav; Oscar Brück; Ashwini Kumar; Hele Everaus; Bjørn T Gjertsen; Merja Heinäniemi; Kimmo Porkka; Satu Mustjoki; Caroline A Heckman
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.